Pharmacist-led quality improvement project to optimize abemaciclib dosing within a community oncology network
NCODA Oncology and Hematology Meeting Abstracts · 13.10.2026 · 2 (2)
DOI: 10.67209/htge4041 ↗Kurz gefasst
Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 13.10.2026. Verfasst von Monica Magoulas und 2 weiteren Autor:innen. Die Arbeit nennt 5 Literaturangaben.
Abstract (Originalsprache)
Background
Dose interruption and/or dose reduction of abemaciclib may be required based on individual safety and tolerability in patients with breast cancer. In the monarchE trial, 43.7% of patients treated with adjuvant abemaciclib required dose reductions, most commonly for diarrhea. Abemaciclib dose reductions were shown to effectively manage adverse events with only 8.9% of patients discontinuing after a dose reduction; however, 52% of patients who discontinued abemaciclib due to an adverse event did not have a prior dose reduction. Data have shown that the efficacy of adjuvant abemaciclib is not compromised by dose reductions for patients with high-risk early breast cancer or advanced breast cancer. Timely evaluations for adverse reactions, a reduced starting dose or dose escalation as used in the TRADE study may allow patients to continue therapy longer and therefore maximize efficacy.
Objective
Implement pharmacist-led interventions to optimize abemaciclib dosing. Improve patient tolerability while maintaining treatment efficacy. Demonstrate the value of pharmacist-driven care in supporting clinical outcomes.
Methods
A quality improvement project was initiated on 7/1/2025 within American Oncology Network (AON) Pharmacy to improve appropriate abemaciclib dosing. Clinical pharmacists standardized (1) patient education for diarrhea management, (2) timeline for follow-up symptom assessments, and (3) dose-adjustment recommendations for new starts and patients experiencing diarrhea. Education was distributed to providers through the Pharmacy and Therapeutics Committee and the Pharmacy Newsletter. Success was measured by evaluating (1) number of pharmacist interventions, (2) intervention success rate (goal 80%), and (3) percentage of patients who discontinued abemaciclib without first having a prior dose reduction (goal 20%). The population evaluated included patients newly started on abemaciclib in both the adjuvant and metastatic settings whose prescriptions were dispensed by AON Pharmacy between 7/1/2025 and 3/31/2026. Data were collected from the dispensing software and OncoEMR.
Results
One hundred sixty-eight patients were started on abemaciclib during the study period. Thirty-one interventions were made by the clinical pharmacists, with an 87% success rate (dose-reduced prescription received following intervention). Only 15% of patients who discontinued abemaciclib during the study period had no dose reduction before discontinuation, versus 30% at baseline and 52% in the monarchE study. Of note, 20% of patients were started at full dose, which represented a decrease from baseline.
Conclusion
This quality improvement project increased appropriate dosing of abemaciclib. Data have shown that reduced starting doses and early dose reductions for toxicity do not compromise efficacy. Provider education at the start of the project and evidence-based recommendations were instrumental in achieving an 87% success rate for pharmacist interventions. We estimate that the decrease in the number of patients who discontinued abemaciclib without first trying a reduced dose translates to a longer duration of therapy and therefore possibly improved efficacy for this patient population. Funding: Not Applicable.
Zitieren
APA
Magoulas, M., Reed, H., & Peters, B. (2026). Pharmacist-led quality improvement project to optimize abemaciclib dosing within a community oncology network. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/htge4041
Vancouver
Magoulas M, Reed H, Peters B. Pharmacist-led quality improvement project to optimize abemaciclib dosing within a community oncology network. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/htge4041
BibTeX
@article{Magoulas2026,
author = {Magoulas, Monica and Reed, Hayley and Peters, Brooke},
title = {Pharmacist-led quality improvement project to optimize abemaciclib dosing within a community oncology network},
journal = {NCODA Oncology and Hematology Meeting Abstracts},
year = {2026},
volume = {2},
number = {2},
doi = {10.67209/htge4041}
}
EUVIMED